<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203564</url>
  </required_header>
  <id_info>
    <org_study_id>ISO-FF-001</org_study_id>
    <nct_id>NCT03203564</nct_id>
  </id_info>
  <brief_title>Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin ® in Healthy Volunteers Tetrahydrofolate in Healthy Male Volunteers</brief_title>
  <official_title>An Adaptive, Randomized, Double-blind, Single-center, Placebo-controlled Phase I Study Evaluating ECG Effects, Safety and Pharmacokinetics of Single Ascending Doses of [6R]-5,10-Methylene Tetrahydrofolate (Modufolin® for Injection, 100mg) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isofol Medical AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isofol Medical AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluating ECG effects, safety, tolerability and
      pharmacokinetics of single ascending dose of Modufolin® in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An adaptive randomised, double-blind, single-centre, placebo-controlled Phase I study
      evaluating ECG effects, safety, tolerability and PK of single ascending doses of Modufolin®
      for Injection, 100 mg in healthy male volunteers. Thirty-three (33) eligible and consenting
      subjects will be included in 3 cohorts, 11 subjects in each cohort. Within each cohort,
      subjects will be randomised to receive either placebo (3 subjects) or Modufolin® for
      Injection, 100 mg (8 subjects). There will be 3 pre-defined ascending dose-levels. Additional
      dose levels may be considered if recommended by the internal Safety Review cCommittee. There
      will be an interval between each dose level to allow time for safety data to be analyzed and
      evaluated by the iSRC. The iSRC will have the choice to decide to escalate the dose as
      planned, reduce or increase the dose escalation step, repeat the dose, reduce the dose or
      terminate the study. The total study duration for the subjects will be approximately 5 weeks
      and there will be in total 3 visits to the clinic. Subjects will be screened for eligibility
      according to study-specific inclusion/exclusion criteria within 4 weeks prior to start of
      stud treatment (Visit 1; Screening visit). The subjects will be confined to the research
      clinic from the evening before dosing (Day -1) until 24 hrs post dose (Days 1 and 2). The
      subjects should be fasting overnight (8 hrs) before IMP/placebo administration until 4 hrs
      post-dose. A Follow-up Visit will be performed 5 to 10 days after dose administration of for
      each cohort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2017</start_date>
  <completion_date type="Actual">August 25, 2017</completion_date>
  <primary_completion_date type="Actual">August 25, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>An adaptive, randomized, double-blind, single-center, placebo-controlled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>IMP (Modufolin® for Injection, 100 mg) and Placebo are not identical in appearance and all efforts will be made at the clinic in order to maintain the blind. Both the IMP and the placebo will be masked in such a way that study subjects and study staff will remain blinded during the study. An un-blinded study nurse will prepare the IMP/placebo for injection and will administer the IMP/placebo to the study subject. The un-blinded study nurse performing the dose administration will not be involved in any study-specific assessments or evaluations.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change-from-baseline QTcF (ΔQTcF)</measure>
    <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
    <description>At each nominal time point specified in the CSP, up to 10 ECG replicates were extracted with TQT Plus methods. TQT Plus ECG extraction technique: Twelve-lead ECGs were extracted from continuous recordings (Holter recordings) prior to and serially after IMP administration at time points as shown in the Schedule of events. Subjects were supinely resting for at least 10 min prior to time points for ECG recordings.
The 12-lead Holter and ECG equipment were supplied and supported by iCardiac Technologies, Inc.
For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min pre-dose) on Day 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship Between ΔΔQTc and Modufolin® (and Metabolites) Plasma Concentrations</measure>
    <time_frame>5 minute post-dose time point</time_frame>
    <description>Predicted ΔΔQTcF interval at geometric mean Cmax for 5,10-MTHF, THF, and 5-Formyl-THF and geometric mean concentration of 5-Methyl-THF observed at 5 minutes post-dose The relationship between plasma concentrations of 5,10-MTHF, THF, 5-Methyl-THF, and 5-Formyl-THF, and change-from-baseline QTcF (ΔQTcF) was quantified using a linear mixed-effects modeling approach with separate analyses for each of the analytes (5,10-MTHF, THF 5-Methyl-THF, and 5-Formyl-THF) initially, with ΔQTcF as the dependent variable, plasma concentration of 5,10-MTHF (or THF, 5-Methyl-THF, or 5-Formyl-THF) as a continuous covariate (i.e., 0 for placebo), centered baseline QTcF as an additional covariate, treatment (active = 1 or placebo = 0) and time (i.e., time point) as categorical factors, and a random intercept and slope per subject. The degrees of freedom estimates were determined by the Kenward-Roger method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline Heart Rate (ΔHR)</measure>
    <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
    <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline PR (ΔPR)</measure>
    <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
    <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline QRS (ΔQRS)</measure>
    <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
    <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Categorical QTcF Outliers</measure>
    <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
    <description>QTcF outliers per absolute category across treatment groups and QTcF outliers per change-from-baseline category (ΔQTcF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Outliers for HR, PR Interval, QRS Interval</measure>
    <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
    <description>Categorical Analysis of outliers for HR, PR, and QRS intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Analysis for T Wave Morphology</measure>
    <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
    <description>Categorical T-wave morphology analysis and measurement of PR and QRS intervals were fully performed manually in three of the 10 ECG replicates at each time point. Final quality control and diagnostic interpretations were performed by the study cardiologist. When the results for each time point were compiled in the final data set, the comparison was made between ECG parameters from the three manually reviewed ECGs versus the 10 ECG replicates for quality control purposes. No treatment emergent T wave morphology changes were observed. In addition to the T-wave categorical analysis, the presence of abnormal U-waves was noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>At visit 1 (screening) and follow-up</time_frame>
    <description>A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities.
Physical examination findings were categorized as Normal, Abnormal non-clinical significant (NCS), and Abnormal clinical significant (CS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).</time_frame>
    <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).</time_frame>
    <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.
There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Pulse</measure>
    <time_frame>Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).</time_frame>
    <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.
There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Laboratory Measurements</measure>
    <time_frame>Pre-dose at screening (visit 1) and -2h (visit 2). Post-dose at following timepoints: 24 h (visit 2) and at follow-up (visit 3)</time_frame>
    <description>The following safety laboratory parameters were assessed:
Clinical Chemistry: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Albumin, Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Chloride, Creatinine, Magnesium, Phosphorous, Potassium, Sodium, Urea nitrogen, Uric acid. Haematology: Haematocrit, Haemoglobin (Hb), Platelet count, Red blood cell (RBC) count, White blood cell (WBC) count with differential count. Urinalysis (dip stick):Glucose, Erythrocytes, Nitrite, Protein, Specific gravity, pH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, Seriousness and Intensity of AEs</measure>
    <time_frame>From start of IMP administration to follow-up visit</time_frame>
    <description>An overall summary of AEs occurring after first administration of IMP (TEAE) is presented by treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: C0</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h. pre-dose to 24 h post-dose</time_frame>
    <description>The mean back-extrapolated concentration at time 0 h (C0) was calculated for MTHF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: C5min</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h</time_frame>
    <description>Measured concentration at 5 min post dose (C5min) of MTHF and 5-Formyl-THF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: AUClast</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: AUClast/Dose</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: Timepoint for Last Measured Plasma Concentration (Tlast)</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: t1/2</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: CL</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: Vss</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: Cmax</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: Tmax</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF</measure>
    <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h</time_frame>
    <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted. Only the metabolite 5-Formyl-THF has values above LLOQ and are presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With AEs</measure>
    <time_frame>From start of IMP administration to follow-up visit</time_frame>
    <description>An overall summary of subjects with AEs occurring after first administration of IMP (TEAE), number of related TEAEs and number of withdrawals due to TEAEs are presented by treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Phase I Study in Healthy Volunteers to Evaluate ECG Effect</condition>
  <arm_group>
    <arm_group_label>Modufolin® for injection, 200, 350 and 500 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% NaCl sterile solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three cohorts, 3 subjects will be randomised to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modufolin®</intervention_name>
    <description>Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)</description>
    <arm_group_label>0.9% NaCl sterile solution</arm_group_label>
    <arm_group_label>Modufolin® for injection, 200, 350 and 500 mg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to provide a written informed consent for participation in the study.

          2. Healthy male subject aged 18-60 years inclusive.

          3. Body Mass Index (BMI) ≥ 18 and ≤ 30 kg/m2 and weight at least 50 kg and no more than
             100 kg at screening and body surface area ≤ 2 m2

          4. Clinically normal medical history, physical findings, vital signs, ECG and laboratory
             values at the time of screening, as judged by the Investigator.

          5. Willing to use condom and highly effective contraceptive methods with a failure rate
             of &lt; 1% to prevent pregnancy1 and drug exposure to a partner and refrain from donating
             sperm from the date of dosing until 3 months after dosing of the IMP/placebo.

        Exclusion Criteria:

          -  1. History of any clinically significant disease or disorder which, in the opinion of
             the Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or subject´s ability to participate in the study.

             2. Any clinically significant illness, medical/surgical procedure or trauma within
             four weeks of the first administration of IMP/placebo. 3. Any planned major surgery
             within the duration of the study. 4. Any positive result on screening for serum
             hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency Virus
             (HIV). 5. After 10 minutes (min) supine rest at the time of screening, any vital signs
             values outside the following ranges:

               -  Systolic BP &gt; 150 mm Hg

               -  Diastolic BP &gt; 90 mm Hg

               -  Pulse &lt; 40 or &gt; 85 beats per min 6. Prolonged QTcF (&gt;450 ms), cardiac arrhythmias
                  or any clinically significant abnormalities in the resting ECG at the time of
                  screening, as judged by the Investigator.

                  7. History of severe allergy/hypersensitivity or on-going
                  allergy/hypersensitivity, as judged by the Investigator, or history of
                  hypersensitivity to drugs with a similar chemical structure or class to
                  Modufolin® (i.e., folate derivatives). 8. Regular use of any prescribed or
                  non-prescribed medication including antacids, analgesics, herbal remedies,
                  vitamins and minerals within two weeks prior to the administration of
                  IMP/placebo, except occasional intake of paracetamol (maximum 2000 mg/day; and
                  not exceeding 3 000 mg/week), at the discretion of the Investigator and nasal
                  decongestants without cortisone or antihistamine for a maximum of 10 days, at the
                  discretion of the Investigator. 9. Regular use of any prescribed or
                  non-prescribed medication which could influence folate and vitamin B12 status
                  within 30 days prior to the administration of IMP/placebo.

                  10. Administration of another new chemical entity (defined as a compound which
                  has not been approved for marketing) or has participated in any other clinical
                  study that included drug treatment with less than three months between
                  administration of last dose and first dose of IMP/placebo in this study. Subjects
                  consented and screened but not dosed in previous phase I studies are not
                  excluded. 11. Current smokers or users of nicotine products. Irregular use of
                  nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per
                  week is allowed before screening visit. 12. Positive screen for drugs of abuse or
                  alcohol at screening or on admission to the unit prior to administration of the
                  IMP/placebo. 13. Current or history of alcohol abuse and/or use of anabolic
                  steroids or drugs of abuse.

                  14. Intake of xanthine and/or taurine containing energy drinks within two days
                  prior to screening.

                  15. Plasma donation within one month of screening or blood donation (or
                  corresponding blood loss) during the three months prior to dosing. 16.
                  Investigator considers the subject unlikely to comply with study procedures,
                  restrictions and requirements.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CTC Clinical Trial Consultants</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <results_first_submitted>November 4, 2019</results_first_submitted>
  <results_first_submitted_qc>March 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2020</results_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03203564/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03203564/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from a database of healthy volunteers at CTC and from advertising in media, including social media.</recruitment_details>
      <pre_assignment_details>Subjects were screened for eligibility according to study-specific inclusion/exclusion criteria within four weeks prior to start of study treatment (Visit 1; Screening Visit).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>200 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="P2">
          <title>350 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="P3">
          <title>500 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>200 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="B2">
          <title>350 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="B3">
          <title>500 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change-from-baseline QTcF (ΔQTcF)</title>
        <description>At each nominal time point specified in the CSP, up to 10 ECG replicates were extracted with TQT Plus methods. TQT Plus ECG extraction technique: Twelve-lead ECGs were extracted from continuous recordings (Holter recordings) prior to and serially after IMP administration at time points as shown in the Schedule of events. Subjects were supinely resting for at least 10 min prior to time points for ECG recordings.
The 12-lead Holter and ECG equipment were supplied and supported by iCardiac Technologies, Inc.
For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min pre-dose) on Day 1.</description>
        <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
        <population>The QT/QTc Analysis Set includes all subjects in the Safety Analysis Set with measurements at baseline as well as on-treatment with at least one post-dose time point with a valid ΔQTcF (change from baseline QTcF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change-from-baseline QTcF (ΔQTcF)</title>
          <description>At each nominal time point specified in the CSP, up to 10 ECG replicates were extracted with TQT Plus methods. TQT Plus ECG extraction technique: Twelve-lead ECGs were extracted from continuous recordings (Holter recordings) prior to and serially after IMP administration at time points as shown in the Schedule of events. Subjects were supinely resting for at least 10 min prior to time points for ECG recordings.
The 12-lead Holter and ECG equipment were supplied and supported by iCardiac Technologies, Inc.
For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min pre-dose) on Day 1.</description>
          <population>The QT/QTc Analysis Set includes all subjects in the Safety Analysis Set with measurements at baseline as well as on-treatment with at least one post-dose time point with a valid ΔQTcF (change from baseline QTcF) value.</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.85"/>
                    <measurement group_id="O2" value="9.2" spread="2.84"/>
                    <measurement group_id="O3" value="8.5" spread="2.87"/>
                    <measurement group_id="O4" value="1.1" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="2.28"/>
                    <measurement group_id="O2" value="9.1" spread="2.28"/>
                    <measurement group_id="O3" value="22.4" spread="2.31"/>
                    <measurement group_id="O4" value="0.0" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.48"/>
                    <measurement group_id="O2" value="7.5" spread="1.47"/>
                    <measurement group_id="O3" value="12.4" spread="1.51"/>
                    <measurement group_id="O4" value="0.2" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.43"/>
                    <measurement group_id="O2" value="2.5" spread="1.42"/>
                    <measurement group_id="O3" value="4.2" spread="1.47"/>
                    <measurement group_id="O4" value="0.8" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.38"/>
                    <measurement group_id="O2" value="-0.7" spread="1.38"/>
                    <measurement group_id="O3" value="-0.9" spread="1.42"/>
                    <measurement group_id="O4" value="1.4" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="1.97"/>
                    <measurement group_id="O2" value="-1.7" spread="1.96"/>
                    <measurement group_id="O3" value="1.0" spread="1.99"/>
                    <measurement group_id="O4" value="0.7" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="2.58"/>
                    <measurement group_id="O2" value="-0.8" spread="2.58"/>
                    <measurement group_id="O3" value="0.9" spread="2.60"/>
                    <measurement group_id="O4" value="3.8" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="2.70"/>
                    <measurement group_id="O2" value="0.7" spread="2.70"/>
                    <measurement group_id="O3" value="0.0" spread="2.72"/>
                    <measurement group_id="O4" value="2.6" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="3.25"/>
                    <measurement group_id="O2" value="2.6" spread="3.37"/>
                    <measurement group_id="O3" value="0.8" spread="3.27"/>
                    <measurement group_id="O4" value="11.5" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.73"/>
                    <measurement group_id="O2" value="-2.5" spread="2.72"/>
                    <measurement group_id="O3" value="-6.7" spread="2.75"/>
                    <measurement group_id="O4" value="6.4" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="2.91"/>
                    <measurement group_id="O2" value="-5.5" spread="2.90"/>
                    <measurement group_id="O3" value="-7.7" spread="2.93"/>
                    <measurement group_id="O4" value="-0.9" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="2.86"/>
                    <measurement group_id="O2" value="-6.6" spread="2.86"/>
                    <measurement group_id="O3" value="-4.1" spread="2.95"/>
                    <measurement group_id="O4" value="2.8" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="2.85"/>
                    <measurement group_id="O2" value="-8.1" spread="2.84"/>
                    <measurement group_id="O3" value="-4.6" spread="3.01"/>
                    <measurement group_id="O4" value="-1.3" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary analysis of QTcF was based on a linear mixed-effects model with change-from-baseline QTcF as the dependent variable, time (categorical), treatment, and time-by-treatment interaction as fixed effects, and baseline QTcF as a covariate. The least-squares (LS) mean and 2-sided 90 % CIs have been calculated for the contrast “Modufolin® versus placebo” at each dose of Modufolin® and each post-dose time point.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>14.12</ci_upper_limit>
            <estimate_desc>Parameter estimate is done for Placebo-corrected change-from baseline QTcF (ΔΔQTcF) for Modufolin 500 mg/m2 at end of infusion.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between ΔΔQTc and Modufolin® (and Metabolites) Plasma Concentrations</title>
        <description>Predicted ΔΔQTcF interval at geometric mean Cmax for 5,10-MTHF, THF, and 5-Formyl-THF and geometric mean concentration of 5-Methyl-THF observed at 5 minutes post-dose The relationship between plasma concentrations of 5,10-MTHF, THF, 5-Methyl-THF, and 5-Formyl-THF, and change-from-baseline QTcF (ΔQTcF) was quantified using a linear mixed-effects modeling approach with separate analyses for each of the analytes (5,10-MTHF, THF 5-Methyl-THF, and 5-Formyl-THF) initially, with ΔQTcF as the dependent variable, plasma concentration of 5,10-MTHF (or THF, 5-Methyl-THF, or 5-Formyl-THF) as a continuous covariate (i.e., 0 for placebo), centered baseline QTcF as an additional covariate, treatment (active = 1 or placebo = 0) and time (i.e., time point) as categorical factors, and a random intercept and slope per subject. The degrees of freedom estimates were determined by the Kenward-Roger method.</description>
        <time_frame>5 minute post-dose time point</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between ΔΔQTc and Modufolin® (and Metabolites) Plasma Concentrations</title>
          <description>Predicted ΔΔQTcF interval at geometric mean Cmax for 5,10-MTHF, THF, and 5-Formyl-THF and geometric mean concentration of 5-Methyl-THF observed at 5 minutes post-dose The relationship between plasma concentrations of 5,10-MTHF, THF, 5-Methyl-THF, and 5-Formyl-THF, and change-from-baseline QTcF (ΔQTcF) was quantified using a linear mixed-effects modeling approach with separate analyses for each of the analytes (5,10-MTHF, THF 5-Methyl-THF, and 5-Formyl-THF) initially, with ΔQTcF as the dependent variable, plasma concentration of 5,10-MTHF (or THF, 5-Methyl-THF, or 5-Formyl-THF) as a continuous covariate (i.e., 0 for placebo), centered baseline QTcF as an additional covariate, treatment (active = 1 or placebo = 0) and time (i.e., time point) as categorical factors, and a random intercept and slope per subject. The degrees of freedom estimates were determined by the Kenward-Roger method.</description>
          <units>msec / ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5,10-MTHF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24111.78" lower_limit="19194.04" upper_limit="30289.52"/>
                    <measurement group_id="O2" value="51566.94" lower_limit="46351.78" upper_limit="57368.87"/>
                    <measurement group_id="O3" value="69012.28" lower_limit="60609.82" upper_limit="78579.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15995.29" lower_limit="13750.28" upper_limit="18606.83"/>
                    <measurement group_id="O2" value="29386.77" lower_limit="26812.58" upper_limit="32208.09"/>
                    <measurement group_id="O3" value="44018.37" lower_limit="40400.31" upper_limit="47960.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.18" lower_limit="176.04" upper_limit="270.40"/>
                    <measurement group_id="O2" value="544.01" lower_limit="435.70" upper_limit="679.25"/>
                    <measurement group_id="O3" value="333.09" lower_limit="279.56" upper_limit="396.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Formyl-THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.43" lower_limit="114.76" upper_limit="765.71"/>
                    <measurement group_id="O2" value="567.17" lower_limit="414.42" upper_limit="776.22"/>
                    <measurement group_id="O3" value="379.33" lower_limit="333.23" upper_limit="431.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ΔΔQTcF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="0.97" upper_limit="7.33"/>
                    <measurement group_id="O2" value="13.25" lower_limit="9.36" upper_limit="17.14"/>
                    <measurement group_id="O3" value="19.88" lower_limit="15.40" upper_limit="24.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change-from-baseline Heart Rate (ΔHR)</title>
        <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
        <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
        <population>QT/QTc population.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change-from-baseline Heart Rate (ΔHR)</title>
          <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
          <population>QT/QTc population.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.91"/>
                    <measurement group_id="O2" value="2.7" spread="1.91"/>
                    <measurement group_id="O3" value="2.0" spread="1.92"/>
                    <measurement group_id="O4" value="-2.1" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.56"/>
                    <measurement group_id="O2" value="7.4" spread="2.55"/>
                    <measurement group_id="O3" value="13.3" spread="2.56"/>
                    <measurement group_id="O4" value="0.0" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.63"/>
                    <measurement group_id="O2" value="3.6" spread="1.63"/>
                    <measurement group_id="O3" value="2.6" spread="1.64"/>
                    <measurement group_id="O4" value="-1.6" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.00"/>
                    <measurement group_id="O2" value="1.3" spread="2.00"/>
                    <measurement group_id="O3" value="3.0" spread="2.00"/>
                    <measurement group_id="O4" value="-0.7" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="1.90"/>
                    <measurement group_id="O2" value="0.0" spread="1.90"/>
                    <measurement group_id="O3" value="-0.9" spread="1.91"/>
                    <measurement group_id="O4" value="-1.3" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.52"/>
                    <measurement group_id="O2" value="-0.1" spread="1.52"/>
                    <measurement group_id="O3" value="-2.6" spread="1.53"/>
                    <measurement group_id="O4" value="-1.8" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.47"/>
                    <measurement group_id="O2" value="0.3" spread="1.46"/>
                    <measurement group_id="O3" value="0.3" spread="1.47"/>
                    <measurement group_id="O4" value="-2.3" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.82"/>
                    <measurement group_id="O2" value="2.0" spread="1.82"/>
                    <measurement group_id="O3" value="0.2" spread="1.83"/>
                    <measurement group_id="O4" value="-3.3" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="2.06"/>
                    <measurement group_id="O2" value="12.4" spread="2.12"/>
                    <measurement group_id="O3" value="8.9" spread="2.06"/>
                    <measurement group_id="O4" value="9.5" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="2.52"/>
                    <measurement group_id="O2" value="12.5" spread="2.52"/>
                    <measurement group_id="O3" value="6.2" spread="2.53"/>
                    <measurement group_id="O4" value="5.4" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="2.24"/>
                    <measurement group_id="O2" value="8.0" spread="2.23"/>
                    <measurement group_id="O3" value="2.5" spread="2.24"/>
                    <measurement group_id="O4" value="2.1" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="2.41"/>
                    <measurement group_id="O2" value="5.3" spread="2.41"/>
                    <measurement group_id="O3" value="3.6" spread="2.54"/>
                    <measurement group_id="O4" value="0.6" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="2.80"/>
                    <measurement group_id="O2" value="5.7" spread="2.80"/>
                    <measurement group_id="O3" value="8.0" spread="3.00"/>
                    <measurement group_id="O4" value="8.6" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change-from-baseline PR (ΔPR)</title>
        <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
        <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
        <population>QT/QTc population</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change-from-baseline PR (ΔPR)</title>
          <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
          <population>QT/QTc population</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.08"/>
                    <measurement group_id="O2" value="-4.4" spread="2.08"/>
                    <measurement group_id="O3" value="-2.1" spread="2.08"/>
                    <measurement group_id="O4" value="-1.6" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.07"/>
                    <measurement group_id="O2" value="-4.5" spread="2.07"/>
                    <measurement group_id="O3" value="-3.1" spread="2.07"/>
                    <measurement group_id="O4" value="-0.1" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="2.61"/>
                    <measurement group_id="O2" value="-1.2" spread="2.61"/>
                    <measurement group_id="O3" value="0.2" spread="2.61"/>
                    <measurement group_id="O4" value="3.8" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.11"/>
                    <measurement group_id="O2" value="-3.7" spread="2.11"/>
                    <measurement group_id="O3" value="1.3" spread="2.11"/>
                    <measurement group_id="O4" value="2.9" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="1.89"/>
                    <measurement group_id="O2" value="-3.6" spread="1.89"/>
                    <measurement group_id="O3" value="-0.3" spread="1.89"/>
                    <measurement group_id="O4" value="0.4" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="2.13"/>
                    <measurement group_id="O2" value="-4.1" spread="2.13"/>
                    <measurement group_id="O3" value="1.1" spread="2.13"/>
                    <measurement group_id="O4" value="3.1" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="2.14"/>
                    <measurement group_id="O2" value="-4.2" spread="2.14"/>
                    <measurement group_id="O3" value="-1.6" spread="2.14"/>
                    <measurement group_id="O4" value="1.2" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="1.84"/>
                    <measurement group_id="O2" value="-4.6" spread="1.84"/>
                    <measurement group_id="O3" value="-2.1" spread="1.84"/>
                    <measurement group_id="O4" value="1.4" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="2.59"/>
                    <measurement group_id="O2" value="-7.1" spread="2.71"/>
                    <measurement group_id="O3" value="-7.8" spread="2.59"/>
                    <measurement group_id="O4" value="-3.5" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="2.04"/>
                    <measurement group_id="O2" value="-8.4" spread="2.04"/>
                    <measurement group_id="O3" value="-5.8" spread="2.04"/>
                    <measurement group_id="O4" value="-3.9" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="2.62"/>
                    <measurement group_id="O2" value="-7.2" spread="2.62"/>
                    <measurement group_id="O3" value="-4.3" spread="2.62"/>
                    <measurement group_id="O4" value="-5.6" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="3.12"/>
                    <measurement group_id="O2" value="-1.5" spread="3.12"/>
                    <measurement group_id="O3" value="-6.9" spread="3.22"/>
                    <measurement group_id="O4" value="-1.7" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="2.77"/>
                    <measurement group_id="O2" value="-5.6" spread="2.77"/>
                    <measurement group_id="O3" value="-6.4" spread="2.88"/>
                    <measurement group_id="O4" value="-6.8" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change-from-baseline QRS (ΔQRS)</title>
        <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
        <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
        <population>QT/QTc population</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change-from-baseline QRS (ΔQRS)</title>
          <description>The analysis was based on the change-from-baseline post-dosing values. The same (by-time point analysis) model was used as described for QTcF. For all ECG parameters, baseline is defined as the average of the measured ECG intervals from the three pre-dose time points (45, 30, and 15 min predose) on Day 1.</description>
          <population>QT/QTc population</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.27"/>
                    <measurement group_id="O2" value="-0.2" spread="0.27"/>
                    <measurement group_id="O3" value="-0.1" spread="0.27"/>
                    <measurement group_id="O4" value="0.5" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.28"/>
                    <measurement group_id="O2" value="-0.8" spread="0.28"/>
                    <measurement group_id="O3" value="-1.2" spread="0.28"/>
                    <measurement group_id="O4" value="0.0" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.25"/>
                    <measurement group_id="O2" value="-0.3" spread="0.25"/>
                    <measurement group_id="O3" value="-0.1" spread="0.25"/>
                    <measurement group_id="O4" value="0.0" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.27"/>
                    <measurement group_id="O2" value="0.0" spread="0.27"/>
                    <measurement group_id="O3" value="-0.5" spread="0.27"/>
                    <measurement group_id="O4" value="0.0" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.26"/>
                    <measurement group_id="O2" value="0.1" spread="0.26"/>
                    <measurement group_id="O3" value="0.2" spread="0.26"/>
                    <measurement group_id="O4" value="0.0" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.22"/>
                    <measurement group_id="O2" value="0.0" spread="0.22"/>
                    <measurement group_id="O3" value="-0.1" spread="0.22"/>
                    <measurement group_id="O4" value="-0.1" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.30"/>
                    <measurement group_id="O2" value="-0.1" spread="0.31"/>
                    <measurement group_id="O3" value="-0.4" spread="0.30"/>
                    <measurement group_id="O4" value="0.2" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.39"/>
                    <measurement group_id="O2" value="-0.5" spread="0.39"/>
                    <measurement group_id="O3" value="0.2" spread="0.38"/>
                    <measurement group_id="O4" value="0.9" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.47"/>
                    <measurement group_id="O2" value="0.4" spread="0.49"/>
                    <measurement group_id="O3" value="0.1" spread="0.47"/>
                    <measurement group_id="O4" value="0.2" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.52"/>
                    <measurement group_id="O2" value="-0.4" spread="0.52"/>
                    <measurement group_id="O3" value="-0.8" spread="0.52"/>
                    <measurement group_id="O4" value="-0.7" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.53"/>
                    <measurement group_id="O2" value="-0.3" spread="0.53"/>
                    <measurement group_id="O3" value="-0.5" spread="0.53"/>
                    <measurement group_id="O4" value="-0.6" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.56"/>
                    <measurement group_id="O2" value="0.3" spread="0.56"/>
                    <measurement group_id="O3" value="-0.6" spread="0.58"/>
                    <measurement group_id="O4" value="-1.0" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.45"/>
                    <measurement group_id="O2" value="0.4" spread="0.45"/>
                    <measurement group_id="O3" value="-0.9" spread="0.47"/>
                    <measurement group_id="O4" value="-0.9" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Categorical QTcF Outliers</title>
        <description>QTcF outliers per absolute category across treatment groups and QTcF outliers per change-from-baseline category (ΔQTcF)</description>
        <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorical QTcF Outliers</title>
          <description>QTcF outliers per absolute category across treatment groups and QTcF outliers per change-from-baseline category (ΔQTcF)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. participants with QTcF &gt; 450 and ≤ 480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. participants with QTcF &gt; 480 and ≤ 500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. participants with QTcF &gt; 500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. participants with ΔQTcF of &gt; 30 and ≤ 60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. participants with ΔQTcF &gt; 60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Outliers for HR, PR Interval, QRS Interval</title>
        <description>Categorical Analysis of outliers for HR, PR, and QRS intervals</description>
        <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Outliers for HR, PR Interval, QRS Interval</title>
          <description>Categorical Analysis of outliers for HR, PR, and QRS intervals</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR changes &gt;25% decrease from baseline to &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR changes &gt;25% increase from baseline to &gt;100bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR changes &gt; 25% increase from baseline to &gt;200ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS changes &gt; 25% increase from baseline to &gt;120ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Analysis for T Wave Morphology</title>
        <description>Categorical T-wave morphology analysis and measurement of PR and QRS intervals were fully performed manually in three of the 10 ECG replicates at each time point. Final quality control and diagnostic interpretations were performed by the study cardiologist. When the results for each time point were compiled in the final data set, the comparison was made between ECG parameters from the three manually reviewed ECGs versus the 10 ECG replicates for quality control purposes. No treatment emergent T wave morphology changes were observed. In addition to the T-wave categorical analysis, the presence of abnormal U-waves was noted.</description>
        <time_frame>Pre-dose at following timepoints -2 h, -45 min, -30 min, -15 min. Then at following timepoints; 0, 5 min, 15 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Analysis for T Wave Morphology</title>
          <description>Categorical T-wave morphology analysis and measurement of PR and QRS intervals were fully performed manually in three of the 10 ECG replicates at each time point. Final quality control and diagnostic interpretations were performed by the study cardiologist. When the results for each time point were compiled in the final data set, the comparison was made between ECG parameters from the three manually reviewed ECGs versus the 10 ECG replicates for quality control purposes. No treatment emergent T wave morphology changes were observed. In addition to the T-wave categorical analysis, the presence of abnormal U-waves was noted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notched (+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biphasic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notched (-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U wave presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Examination</title>
        <description>A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities.
Physical examination findings were categorized as Normal, Abnormal non-clinical significant (NCS), and Abnormal clinical significant (CS).</description>
        <time_frame>At visit 1 (screening) and follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Examination</title>
          <description>A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities.
Physical examination findings were categorized as Normal, Abnormal non-clinical significant (NCS), and Abnormal clinical significant (CS).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal NCS - Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal CS - Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal NCS - Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal CS - Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.</description>
        <time_frame>Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.50" spread="7.60"/>
                    <measurement group_id="O2" value="121.25" spread="7.07"/>
                    <measurement group_id="O3" value="116.63" spread="9.56"/>
                    <measurement group_id="O4" value="125.56" spread="14.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (-00:15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.38" spread="10.94"/>
                    <measurement group_id="O2" value="109.38" spread="9.36"/>
                    <measurement group_id="O3" value="117.38" spread="8.11"/>
                    <measurement group_id="O4" value="123.67" spread="24.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (03:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.88" spread="7.12"/>
                    <measurement group_id="O2" value="105.00" spread="6.89"/>
                    <measurement group_id="O3" value="112.50" spread="9.29"/>
                    <measurement group_id="O4" value="111.22" spread="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (05:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.50" spread="5.61"/>
                    <measurement group_id="O2" value="115.00" spread="8.50"/>
                    <measurement group_id="O3" value="120.88" spread="7.94"/>
                    <measurement group_id="O4" value="113.00" spread="13.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (08:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.50" spread="9.06"/>
                    <measurement group_id="O2" value="113.88" spread="6.75"/>
                    <measurement group_id="O3" value="115.63" spread="5.83"/>
                    <measurement group_id="O4" value="114.89" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.75" spread="9.29"/>
                    <measurement group_id="O2" value="114.13" spread="5.77"/>
                    <measurement group_id="O3" value="120.88" spread="8.46"/>
                    <measurement group_id="O4" value="119.00" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.38" spread="8.93"/>
                    <measurement group_id="O2" value="115.63" spread="11.03"/>
                    <measurement group_id="O3" value="119.38" spread="10.21"/>
                    <measurement group_id="O4" value="122.11" spread="12.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.
There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.</description>
        <time_frame>Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.
There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.63" spread="5.21"/>
                    <measurement group_id="O2" value="69.75" spread="8.51"/>
                    <measurement group_id="O3" value="72.25" spread="8.01"/>
                    <measurement group_id="O4" value="73.56" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (-00:15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.63" spread="3.74"/>
                    <measurement group_id="O2" value="65.88" spread="6.42"/>
                    <measurement group_id="O3" value="75.38" spread="2.77"/>
                    <measurement group_id="O4" value="69.56" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (03:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.00" spread="6.89"/>
                    <measurement group_id="O2" value="64.38" spread="7.37"/>
                    <measurement group_id="O3" value="72.63" spread="5.71"/>
                    <measurement group_id="O4" value="65.56" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (05:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.63" spread="5.88"/>
                    <measurement group_id="O2" value="62.38" spread="5.04"/>
                    <measurement group_id="O3" value="72.25" spread="7.15"/>
                    <measurement group_id="O4" value="67.00" spread="11.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (08:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.00" spread="7.29"/>
                    <measurement group_id="O2" value="64.50" spread="3.89"/>
                    <measurement group_id="O3" value="70.25" spread="6.36"/>
                    <measurement group_id="O4" value="66.22" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.50" spread="10.23"/>
                    <measurement group_id="O2" value="69.38" spread="4.50"/>
                    <measurement group_id="O3" value="74.25" spread="5.47"/>
                    <measurement group_id="O4" value="71.11" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.25" spread="4.53"/>
                    <measurement group_id="O2" value="70.25" spread="7.81"/>
                    <measurement group_id="O3" value="71.00" spread="8.07"/>
                    <measurement group_id="O4" value="70.11" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Pulse</title>
        <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.
There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.</description>
        <time_frame>Predose at following timepoints: At screening (visit 1) and at -15 min (visit 2). Postdose at following timepoints: 3h, 5h, 8 h and 24h (visit 2) and at visit 3 (follow-up visit).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Pulse</title>
          <description>Systolic and diastolic BP and pulse were measured in supine position after 10 min of rest.
There were no clinically relevant mean changes over time or any individual changes assessed as clinically significant with regards to any of the vital signs parameters.</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.50" spread="5.21"/>
                    <measurement group_id="O2" value="66.50" spread="9.38"/>
                    <measurement group_id="O3" value="62.00" spread="11.24"/>
                    <measurement group_id="O4" value="63.22" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (-00:15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.25" spread="5.44"/>
                    <measurement group_id="O2" value="52.00" spread="8.60"/>
                    <measurement group_id="O3" value="56.38" spread="5.58"/>
                    <measurement group_id="O4" value="54.44" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 03:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.25" spread="5.50"/>
                    <measurement group_id="O2" value="53.13" spread="11.01"/>
                    <measurement group_id="O3" value="53.75" spread="4.95"/>
                    <measurement group_id="O4" value="50.33" spread="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (05:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.38" spread="4.00"/>
                    <measurement group_id="O2" value="65.25" spread="9.66"/>
                    <measurement group_id="O3" value="66.00" spread="11.60"/>
                    <measurement group_id="O4" value="61.44" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 1 (08:00)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.25" spread="6.82"/>
                    <measurement group_id="O2" value="59.00" spread="5.83"/>
                    <measurement group_id="O3" value="56.75" spread="7.21"/>
                    <measurement group_id="O4" value="55.67" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.38" spread="9.53"/>
                    <measurement group_id="O2" value="57.63" spread="8.91"/>
                    <measurement group_id="O3" value="61.75" spread="13.48"/>
                    <measurement group_id="O4" value="61.22" spread="11.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.25" spread="9.04"/>
                    <measurement group_id="O2" value="67.88" spread="12.91"/>
                    <measurement group_id="O3" value="69.25" spread="16.26"/>
                    <measurement group_id="O4" value="67.44" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Laboratory Measurements</title>
        <description>The following safety laboratory parameters were assessed:
Clinical Chemistry: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Albumin, Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Chloride, Creatinine, Magnesium, Phosphorous, Potassium, Sodium, Urea nitrogen, Uric acid. Haematology: Haematocrit, Haemoglobin (Hb), Platelet count, Red blood cell (RBC) count, White blood cell (WBC) count with differential count. Urinalysis (dip stick):Glucose, Erythrocytes, Nitrite, Protein, Specific gravity, pH.</description>
        <time_frame>Pre-dose at screening (visit 1) and -2h (visit 2). Post-dose at following timepoints: 24 h (visit 2) and at follow-up (visit 3)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Laboratory Measurements</title>
          <description>The following safety laboratory parameters were assessed:
Clinical Chemistry: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Albumin, Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Chloride, Creatinine, Magnesium, Phosphorous, Potassium, Sodium, Urea nitrogen, Uric acid. Haematology: Haematocrit, Haemoglobin (Hb), Platelet count, Red blood cell (RBC) count, White blood cell (WBC) count with differential count. Urinalysis (dip stick):Glucose, Erythrocytes, Nitrite, Protein, Specific gravity, pH.</description>
          <units>Clinically relevant changes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency, Seriousness and Intensity of AEs</title>
        <description>An overall summary of AEs occurring after first administration of IMP (TEAE) is presented by treatment</description>
        <time_frame>From start of IMP administration to follow-up visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency, Seriousness and Intensity of AEs</title>
          <description>An overall summary of AEs occurring after first administration of IMP (TEAE) is presented by treatment</description>
          <population>FAS</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. of TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of subject-unique TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject-unique related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: C0</title>
        <description>The mean back-extrapolated concentration at time 0 h (C0) was calculated for MTHF</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h. pre-dose to 24 h post-dose</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: C0</title>
          <description>The mean back-extrapolated concentration at time 0 h (C0) was calculated for MTHF</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34200" spread="10300"/>
                    <measurement group_id="O2" value="78300" spread="12600"/>
                    <measurement group_id="O3" value="99000" spread="23100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: C5min</title>
        <description>Measured concentration at 5 min post dose (C5min) of MTHF and 5-Formyl-THF</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: C5min</title>
          <description>Measured concentration at 5 min post dose (C5min) of MTHF and 5-Formyl-THF</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MTHF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24600" spread="6480"/>
                    <measurement group_id="O2" value="52200" spread="8530"/>
                    <measurement group_id="O3" value="70100" spread="13100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Formyl-THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443" spread="432"/>
                    <measurement group_id="O2" value="609" spread="240"/>
                    <measurement group_id="O3" value="374" spread="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: AUClast</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: AUClast</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MTHF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10900" spread="1680"/>
                    <measurement group_id="O2" value="19700" spread="1990"/>
                    <measurement group_id="O3" value="31100" spread="3210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31800" spread="3780"/>
                    <measurement group_id="O2" value="53100" spread="10000"/>
                    <measurement group_id="O3" value="90100" spread="17500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23400" spread="4470"/>
                    <measurement group_id="O2" value="38500" spread="6380"/>
                    <measurement group_id="O3" value="47400" spread="7540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: AUClast/Dose</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: AUClast/Dose</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>(h*ng/mL)/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MTHF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="5.27"/>
                    <measurement group_id="O2" value="29.8" spread="2.74"/>
                    <measurement group_id="O3" value="32.9" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="11.8"/>
                    <measurement group_id="O2" value="80.1" spread="14.0"/>
                    <measurement group_id="O3" value="95.0" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="12.5"/>
                    <measurement group_id="O2" value="58.3" spread="9.87"/>
                    <measurement group_id="O3" value="49.9" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Formyl-THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="1.97"/>
                    <measurement group_id="O2" value="1.24" spread="1.22"/>
                    <measurement group_id="O3" value="0.343" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: Timepoint for Last Measured Plasma Concentration (Tlast)</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification (LLOQ).</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: Timepoint for Last Measured Plasma Concentration (Tlast)</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification (LLOQ).</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MTHF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="1.95"/>
                    <measurement group_id="O2" value="5.37" spread="1.30"/>
                    <measurement group_id="O3" value="6.75" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.01" spread="1.52"/>
                    <measurement group_id="O2" value="8.01" spread="0.0178"/>
                    <measurement group_id="O3" value="8.75" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="0.0339"/>
                    <measurement group_id="O2" value="24.0" spread="0.0980"/>
                    <measurement group_id="O3" value="23.8" spread="0.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Formyl-THF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="2.94"/>
                    <measurement group_id="O2" value="3.00" spread="2.92"/>
                    <measurement group_id="O3" value="1.40" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: t1/2</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted:</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: t1/2</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted:</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MTHF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" spread="0.936"/>
                    <measurement group_id="O2" value="1.87" spread="0.634"/>
                    <measurement group_id="O3" value="2.03" spread="0.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.211"/>
                    <measurement group_id="O2" value="1.51" spread="0.267"/>
                    <measurement group_id="O3" value="1.59" spread="0.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.54" spread="0.714"/>
                    <measurement group_id="O2" value="5.66" spread="0.644"/>
                    <measurement group_id="O3" value="5.84" spread="0.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: CL</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: CL</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted.</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MTHF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="1.84"/>
                    <measurement group_id="O2" value="35.5" spread="3.05"/>
                    <measurement group_id="O3" value="30.6" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="1.47"/>
                    <measurement group_id="O2" value="12.6" spread="2.58"/>
                    <measurement group_id="O3" value="10.7" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="3.11"/>
                    <measurement group_id="O2" value="16.5" spread="2.63"/>
                    <measurement group_id="O3" value="19.1" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: Vss</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: Vss</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MTHF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="9.38"/>
                    <measurement group_id="O2" value="20.4" spread="6.10"/>
                    <measurement group_id="O3" value="18.5" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="3.30"/>
                    <measurement group_id="O2" value="24.9" spread="4.17"/>
                    <measurement group_id="O3" value="21.6" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" spread="28.4"/>
                    <measurement group_id="O2" value="153" spread="27.4"/>
                    <measurement group_id="O3" value="181" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: Cmax</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: Cmax</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16400" spread="3610"/>
                    <measurement group_id="O2" value="29600" spread="3970"/>
                    <measurement group_id="O3" value="44400" spread="6090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2490" spread="450"/>
                    <measurement group_id="O2" value="3950" spread="755"/>
                    <measurement group_id="O3" value="4740" spread="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Formyl-THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="642" spread="474"/>
                    <measurement group_id="O2" value="619" spread="257"/>
                    <measurement group_id="O3" value="386" spread="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: Tmax</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h.</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: Tmax</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267" spread="0.334"/>
                    <measurement group_id="O2" value="0.123" spread="0.0786"/>
                    <measurement group_id="O3" value="0.300" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Methyl-THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="0.835"/>
                    <measurement group_id="O2" value="3.50" spread="1.07"/>
                    <measurement group_id="O3" value="3.63" spread="0.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-Formyl-THF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0778" spread="0.0255"/>
                    <measurement group_id="O2" value="0.102" spread="0.0601"/>
                    <measurement group_id="O3" value="0.142" spread="0.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF</title>
        <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted. Only the metabolite 5-Formyl-THF has values above LLOQ and are presented below.</description>
        <time_frame>Pre-dose at -15 min and post-dose at following timepoints: 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h</time_frame>
        <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK Characteristics: Cmax/Dose for Metabolite 5-Formyl-THF</title>
          <description>Pharmacokinetic parameters were calculated for test item MTHF, and for the following metabolites: 5-Formyl-THF, 5-Methyl-THF, and THF, if data permitted. Only the metabolite 5-Formyl-THF has values above LLOQ and are presented below.</description>
          <population>All samples analysed from the subjects given placebo were below Lower Limit of Quantification.</population>
          <units>ng/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="1.33"/>
                    <measurement group_id="O2" value="0.934" spread="0.379"/>
                    <measurement group_id="O3" value="0.407" spread="0.0826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With AEs</title>
        <description>An overall summary of subjects with AEs occurring after first administration of IMP (TEAE), number of related TEAEs and number of withdrawals due to TEAEs are presented by treatment</description>
        <time_frame>From start of IMP administration to follow-up visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O2">
            <title>350 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O3">
            <title>500 mg/m2 of Modufolin®</title>
            <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With AEs</title>
          <description>An overall summary of subjects with AEs occurring after first administration of IMP (TEAE), number of related TEAEs and number of withdrawals due to TEAEs are presented by treatment</description>
          <population>FAS</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at least one TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawals due to TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from start of IMP administration to last subject last visit, thus during a period of little less than 2 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>200 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 200 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="E2">
          <title>350 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 350 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="E3">
          <title>500 mg/m2 of Modufolin®</title>
          <description>8 subjects were treated with 500 mg/m2 of Modufolin® as an intravenous bolus injection.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>9 subjects were treated with placebo as an intravenous bolus injection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Non-disclosure agreement that prohibits the PI to communicate results without a prior permission from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Isofol Medical AB</organization>
      <phone>+46 (0)707646500</phone>
      <email>karin.ganlov@isofolmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

